An Alternative Remedy for Cancer – The Molecular Target Drugs
February 19th, 2012 | 
Author: The introduction of biotechnology put on cancer researchers have allowed, with the identification of molecules that talk with a certain molecular target, to look at the alternative treatments of cancer using a hint of optimism. In the future cancer care can be increasingly specific and selective and, therefore, less invasive, and it to hit only the tumor cells.
The creation of antibodies is among the most advanced forms available to man to address foreign invaders (viruses, bacteria) and internal (cancer). Unfortunately, cancer cells, by implementing some strategies escape from the antibody recognition and thus lower their potential defensiveness. Mutations of the protein present on certain tumor cells behave as switches always on, always with all the response to stimulating malignant cell proliferation.
Hence the theory (since 1975) to produce the “monoclonal antibodies”, or laboratory-made antibodies able to bind selectively the antigen (protein) present only on tumor cells. They may be therefore highly specific drugs. Currently more than one thousand prescription medication is being tested, but only several dozen are in use for many types of cancer.
Research offers today a variety of specific agents for molecular targets: molecular antibodies forwarded to block cell proliferation with the epidermal growth factor receptor (EGFR) protein tyrosine kinase inhibitors, farnesyl inhibitors of the RAS oncoprotein, angiogenesis inhibitors (which inhibit the circulation to the tumor with the interruption of the creation of new blood vessels), etc…
For many types of cancer some drugs have proved very effective.
For example, in chronic myeloid leukemia drug tyrosine kinase inhibitor Gleevec makes a positive clinical response in almost all cases.
The limitation of those drugs isn’t necessarily the fact that the antigen is expressed by tumor cells. More precisely, as argued by the same a Director of the Institute of Oncology, University Hospital of Padua Company, “not all cancer cells express the prospective by which the prescription medication is directed. This may also happen that this monoclonal antibody won’t directly act on the active cell, but is blocked by the antigen in the blood circulating tumor and therefore does not matter given it can’t reach the biological target to which it’s built. ” Moreover, oftentimes, though precise and efficient, the monoclonal antibody drug is not sufficient to fully inhibit the roll-out of the disease. Often, the tumor growth is not stuck just using a single factor.I hope above mentioned all alternative treatments for cancer are really effective.
Posted in 
Tags: